Peripheral neuropathy decisions — 2025

The Board denied service connection for obstructive sleep apnea, diabetes mellitus, type II, and diabetic peripheral neuropathy of the bilateral upper and lower extremities as they were not incurred in or caused by the Veteran's military service.

The Board remands the claims for service connection for a neck condition, left arm condition, and left hand condition as there is a need for additional evidence.

The Board granted service connection for right lower extremity radiculopathy as secondary to a service-connected low back disability, but denied service connection for left lower extremity neuropathy.

The Board denied service connection for erectile dysfunction and remanded the claims for bilateral peripheral neuropathy of both upper and lower extremities due to a lack of evidence supporting a current diagnosis.

The Veteran's service-connected erectile dysfunction results in a diminishment of the ability of his creative organ to function, warranting special monthly compensation under 38 U.S.C. 1114(k).

The Board remands the claims for an increased rating for hypothyroidism and entitlement to TDIU due to inadequate examination reports.

The Board granted an earlier effective date of February 17, 2021, for the award of increased disability ratings of 20 percent for peripheral neuropathy in both lower extremities but denied increased ratings and other claims.

The Board remanded the appeal for further development and adjudication of higher ratings and effective dates for various peripheral neuropathies associated with NHL, as well as an earlier effective date for a TDIU rating.

The Board denied the Veteran's claim for service connection for peripheral neuropathy of the left upper extremity, finding no current disability. The claim for service connection for left elbow lateral epicondylitis with tendinitis was remanded for further development.

The Board granted an earlier effective date of February 17, 2021, for the award of increased disability ratings of 20 percent for peripheral neuropathy in both lower extremities but denied increased ratings and other claims.

The Board granted service connection for left knee meniscal tear, right knee osteoarthritis, and persistent depressive disorder with anxious distress secondary to service-connected hypothyroidism. The claims for peripheral neuropathy of the lower extremities were denied.

The Board granted a 30 percent rating for diabetic peripheral neuropathy in the left and right lower extremities but denied higher ratings for diabetic nephropathy, diabetes mellitus type II, and other claims.

The Board granted an effective date of September 6, 2023, for the grant of service connection for right and left upper extremity diabetic peripheral neuropathy.

The Board remands the claims for a higher rating of PTSD and service connection for various peripheral neuropathies, lipomas, and chloracne due to inadequate medical examinations.

The Board remands the Veteran's claims for service connection for peripheral neuropathy in all extremities due to a lack of compliance with previous remand directives.

The Board granted service connection for coronary artery disease, diabetes mellitus type 2, bilateral lower extremity peripheral neuropathy (secondary to diabetes), sleep apnea, and a back disability.

The appeal was dismissed as a timely substantive appeal to the October 2017 rating decision was not received.

The Veteran's peripheral neuropathy of the left and right lower extremities, sciatic nerve was granted a rating of 40 percent prior to October 2, 2023, but denied an increased rating from that date. The Veteran was also granted TDIU and DEA benefits.

The appeal regarding service connection for an acquired psychiatric disorder was dismissed, but the Veteran's claims for direct service connection for chronic inflammatory demyelinating polyneuropathy and an initial 10 percent rating for hypertension were granted. The claim for service connection for GERD was remanded.

The Board granted earlier effective dates for the increased ratings of peripheral neuropathy in all extremities and an earlier effective date for TDIU and DEA benefits.